2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B0389S10
    D-Glucose-13C 101615-88-7 ≥99.0%
    D-Glucose-13C is the 13C labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].
    D-Glucose-13C
  • HY-W014423S4
    L-Histidine-d5 hydrochloride hydrate 2483831-75-8 99.63%
    L-Histidine-d5 (hydrochloride hydrate) is the deuterium labeled L-Histidine hydrochloride hydrate. L-Histidine hydrochloride hydrate (H-His-OH.HCl.H2O) is an endogenous metabolite.
    L-Histidine-d5 hydrochloride hydrate
  • HY-124410
    Mitoquinol 845959-55-9 98.00%
    Mitoquinol is a mitochondrial-targeted coenzyme Q analog. Mitoquinol is an antioxidant that inhibits lipid peroxidation. Mitoquinol can be used in vascular disease research.
    Mitoquinol
  • HY-143239
    PPARα/γ agonist 1 99.68%
    PPARα/γ agonist 1 (compound 5b) is a potent and dual PPARα/γ partial agonist with EC50 values of 28 nM and 69 nM for PPARα and PPARγ, respectively. PPARα/γ agonist 1 is a promising prototype for dyslipidemia and diabetes research.
    PPARα/γ agonist 1
  • HY-A0181S1
    Adenosine monophosphate-15N5 dilithium
    Adenosine monophosphate-15N5 dilithium is the 15N labeled Adenosine monophosphate (HY-A0181). Adenosine monophosphate is an adenosine A1 receptor agonist. Adenosine monophosphate has significant antiviral activity against HSV-1 and HSV-2. Adenosine monophosphate is a key cellular metabolite regulating energy homeostasis and signal transduction.
    Adenosine monophosphate-15N5 dilithium
  • HY-12525
    LGD-6972 1207989-09-0 ≥98.0%
    LGD-6972 is a selective and orally active glucagon receptor antagonist. LGD-6972 has the potential for type 2 diabetes research.
    LGD-6972
  • HY-16747
    Maralixibat chloride 228113-66-4 99.08%
    Maralixibat (SHP625) chloride is an orally active ileal bile acid transporter (IBAT) inhibitor. Maralixibat chloride can be used for the research of rare cholestatic liver diseases including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia.
    Maralixibat chloride
  • HY-100186
    GSK-2881078 1539314-06-1 99.74%
    GSK-2881078 is an orally active and nonsteroidal selective androgen receptor modulator (SARM) which act as partial AR agonists in androgenic tissues while mainly as complete AR agonists in synthetic metabolic tissues,induces AR-mediated transcriptional activation in PC3(AR)2 cells (EC50 = 3.99 nM) and the effect can be inhibited by the non-steroidal AR antagonist Bicalutamide. GSK-2881078 can be used in research of muscle weakness and cachexia associated with both chronic and acute illness.
    GSK-2881078
  • HY-112065
    PF-06869206 2227425-05-8 99.88%
    PF-06869206 is an orally bioavailable selective inhibitor of the sodium-phosphate cotransporter NaPi2a (SLC34A1) with an IC50 of 380 nM.
    PF-06869206
  • HY-12648A
    FASN-IN-4 tosylate 2095432-57-6 98.55%
    FASN-IN-4 tosylate is a potent inhibitor of fatty acid synthase (FASN) with an IC50 of 10 nM (WO2012064642A1, compound 29). FASN-IN-4 tosylate also inhibits SARS-CoV-2 with an EC50 of 18.6?nM.
    FASN-IN-4 tosylate
  • HY-129035
    PFI-653 2173134-00-2 99.92%
    PFI-653 (Vanin-1-IN-1, compound 3) is a vanin-1 inhibitor that binds to plasma vanin-1 from mouse, rat, dog, and human. Vanin-1 is a cell surface-associated inositol (GPi) -anchored protein that plays important roles in metabolism and inflammation. PFI-653 inhibits vanin-1 from different species with IC50s of 6.85 nM (human recombinant plasma vanin-1), 9.0 nM (human plasma vanin-1), 24.5 nM (mouse recombinant vanin-1), and 53.4 nM (mouse plasma vanin-1).
    PFI-653
  • HY-14860A
    1-Deoxynojirimycin hydrochloride 73285-50-4 ≥98.0%
    1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin hydrochloride possesses antihyperglycemic, anti-obesity, and antiviral features.
    1-Deoxynojirimycin hydrochloride
  • HY-10595
    RO-28-1675 300353-13-3 99.95%
    RO-28-1675 is a potent allosteric glucokinase (GK) activator with an EC50 of 54 nM. RO-28-1675 can be used for the research of type 2 diabetes.
    RO-28-1675
  • HY-15157
    Calcitetrol 72203-93-1 99.86%
    Calcitetrol(1α, 24, 25-Trihydroxy VD3) is the hormonally active form of vitamin D with three hydroxyl groups.
    Calcitetrol
  • HY-101449
    Adaptaquin 385786-48-1 99.87%
    Adaptaquin is a BBB-penatrable HIF-PHDs inhibitor. Adaptaquin has anti-inflammatory and neuroprotective effects. Adaptaquin can effectively inhibit lipid peroxidation, maintain mitochondrial function, and reduce neuronal death. Adaptaquin can be used in the research of nervous system diseases such as Parkinson's disease.
    Adaptaquin
  • HY-117103
    AMG131 315224-26-1 99.64%
    AMG131 (INT131) is a potent non-thiazolidinedione (TZD) selective peroxisome proliferator-activated receptor γ modulator (SPPARM). AMG131 binds to PPARγ within the same binding pocket as the TZDs, but occupies a unique space in the pocket and contacts the receptor at distinct points from the TZDs. AMG131 is promising for research of type-2 diabetes mellitus.
    AMG131
  • HY-15991A
    Tenapanor hydrochloride 1234365-97-9 98.71%
    Tenapanor (AZD1722) hydrochloride is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor hydrochloride reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor hydrochloride has the potential for the research of hyperphosphatemia.
    Tenapanor hydrochloride
  • HY-P0119A
    Lixisenatide acetate 1997361-87-1 99.65%
    Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist that can be used in the treatment of type 2 diabetes mellitus (T2DM).
    Lixisenatide acetate
  • HY-15411
    MK-0557 328232-95-7 99.80%
    MK-0557 is a highly selective, orally available neuropeptide Y5 receptor antagonist with a Ki of 1.6 nM.
    MK-0557
  • HY-18346
    Mozavaptan 137975-06-5 99.71%
    Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment.
    Mozavaptan
Cat. No. Product Name / Synonyms Application Reactivity